{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-25-000170","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.798471+00:00","generated_at":"2026-05-18T06:20:19.427828+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)","bullets":["Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).","GAAP net earnings $5,537M; diluted EPS $2.29 vs $1.93 a year ago (+18.7%).","Adjusted net earnings $6,699M; adjusted diluted EPS $2.77 vs $2.82 (-1.8%).","Innovative Medicine sales $15,202M (+4.9%); MedTech sales $8,541M (+7.3%).","Gross margin 67.9% vs 69.4% year ago; R&D expense $3,516M (14.8% of sales)."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-25-000170","json":"https://secwatch.observer/filing/0000200406-25-000170.json","markdown":"https://secwatch.observer/filing/0000200406-25-000170.md","text":"https://secwatch.observer/filing/0000200406-25-000170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/0000200406-25-000170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:20:19.427828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}